Holen Sie sich die Stockscreener-App
14.75
9.42%
1.27
Vorhandelsmarkt:
15.27
0.52
+3.53%
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
EyePoint Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.com.au
Cormorant Asset Management (EYPT) reports 7,000,000 EyePoint shares in 13G/A - Stock Titan
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System - MarketBeat
EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing - simplywall.st
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals, Inc. (EYPT) options chain - Yahoo Finance UK
Adage Capital discloses 4.79M-share EyePoint, Inc. (EYPT) position in Schedule 13G - Stock Titan
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - Kalkine
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Eyepoint Pharma earnings missed by $0.15, revenue topped estimates - Investing.com Nigeria
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Negative Outlook for EYPT Earnings - MarketBeat
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharma nears key Phase III data for DU... - pluang.com
EyePoint: Phase 3 Design Creates A More Valuable Durability Story (NASDAQ:EYPT) - Seeking Alpha
EyePoint Is Maintained at Buy by Chardan Capital - Moomoo
EYPT Maintained by Chardan Capital -- Price Target Remains at $6 - GuruFocus
Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 218% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results - MarketBeat
EYPT Maintained by Cantor Fitzgerald -- Price Target Raised to $55 - GuruFocus
EyePoint, Inc. Stock 12‑Month Price Target Cut to $40.86, Implies 234% Upside - TradingView
EYPT Maintains by HC Wainwright & Co. -- Price Target Lowered to $27 - GuruFocus
HC Wainwright Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald - MarketBeat
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $55 - Moomoo
Is EyePoint Inc (EYPT) Worth the Price After Q2 Earnings Miss? G - GuruFocus
EyePoint, Inc. 2Q 2026: Revenue $507K, Net loss $(94.47M), EPS $(1.09) — 10-Q Summary - TradingView
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
EyePoint Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000 - marketscreener.com
EYPT Looks 1591.3% Overvalued on GF Value™ - GuruFocus
EyePoint: Q2 Earnings Snapshot - marketscreener.com
EyePoint Pharmaceuticals Q2 revenue drops on lower license income - TradingView
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Q2 revenue falls to $0.5 million as Phase 3 data nears - Quiver Quantitative
EYPT: Q2 2026 featured higher R&D costs and a $94.5M net loss as DURAVYU Phase 3 trials progressed - TradingView
EyePoint reports Q2 loss of $94.5M, cash and investments $180M; LUGANO topline due Aug 2026 - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, Vs. FactSet Est of $390,000 - Moomoo
EyePoint, Inc. (Nasdaq: EYPT) widens loss as DURAVYU Phase 3 trials near key data - Stock Titan
Eyepoint Pharma earnings on deck ahead of pivotal trial data - Investing.com
Eyepoint Pharma earnings on deck ahead of pivotal trial data By Investing.com - Investing.com South Africa
EYPT: DURAVYU advances as a potential first-in-class, long-acting TKI for major retinal diseases - TradingView
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.3%Here's Why - MarketBeat
Janus Henderson Group PLC Grows Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Price to earnings forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Vanguard Capital Management (EYPT) discloses 4.22M-share, 5.03% holding in EyePoint - Stock Titan
EyePoint completes enrollment in two phase 3 DME trials By Investing.com - Investing.com South Africa
EyePoint completes enrollment in Phase 3 DME trials; 480+ patients, topline data due 4Q 2027 - TradingView
EYEPOINT INC : MIZUHO RAISES TARGET PRICE TO $39 FROM $36 - Moomoo
EyePoint Completes Enrollment of Both Pivotal Phase 3 - GlobeNewswire
Eyepoint Completes Enrollment of Both Pivotal Phase 3 Trials of Duravyu for Treatment of Diabetic Macular Edema - marketscreener.com
Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating - marketscreener.com
Mizuho raises EyePoint stock price target to $39 on trial outlook - Investing.com South Africa
EYPT Q2'26 Earnings: revenue estimate is 386.57K USD - TradingView
U.S. cracks down on EyePoint over alleged kickbacks, company to pay $4.66 million settlement - Peoples Gazette Nigeria
Did EyePoint's (EYPT) Federal Settlement and 5‑Year Integrity Deal Just Reframe Its Risk Profile? - simplywall.st
BlackRock, Inc. (NASDAQ: EYPT) discloses 7.7% beneficial stake in EyePoint - Stock Titan
EYPT|EyePoint Pharmaceuticals Inc|Price:12.405|Chg%:+0.215 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc - TradingKey
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):